Peptide Comparison
GHK-Cu vs AHK-Cu
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
GHK-Cu and AHK-Cu share the copper-peptide class and carry roughly equivalent evidence (Cosmetic Clinical + Animal Studies / Cosmetic Clinical Studies). On the catalogued data layer GHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK-Cu's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHK-Cu | AHK-Cu | |
|---|---|---|
| Class | Matrikine copper-tripeptide | Copper tripeptide (cosmetic) |
| Drug class | Tissue Repair | Dermatologic |
| Mechanism | Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp |
| Route | Topical / SC / Microneedling | Topical |
| Half-life | Varies by formulation | Topical (no systemic) |
| Dosage (research) | Topical 0.05-2% (cosmetic standard); 1 mg SC daily (Seeds Vol 1 starting dose, range up to 3 mg/day per r/Peptides wiki); microneedling 0.1-0.5% | Topical 0.01-0.1% |
| Evidence tier | Cosmetic Clinical + Animal Studies | Cosmetic Clinical Studies |
| Research depth | 122 indexed | 5 indexed |
| Availability | Cosmetic / Research | Cosmetic |
| Reported risks | Injection site irritation; theoretical copper toxicity at high doses; limited systemic safety data | Skin irritation; theoretical copper issues |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHK-Cu or AHK-Cu?
GHK-Cu and AHK-Cu share the copper-peptide class and carry roughly equivalent evidence (Cosmetic Clinical + Animal Studies / Cosmetic Clinical Studies). On the catalogued data layer GHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK-Cu's evidence base is currently denser.
What is the difference between GHK-Cu and AHK-Cu?
GHK-Cu is classed as Matrikine copper-tripeptide; AHK-Cu is classed as Copper tripeptide (cosmetic). Reported mechanism: GHK-Cu, Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis; AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp. Reported half-life: GHK-Cu, Varies by formulation; AHK-Cu, Topical (no systemic). Routes in published studies: GHK-Cu, Topical / SC / Microneedling; AHK-Cu, Topical.
Which has stronger evidence, GHK-Cu or AHK-Cu?
GHK-Cu and AHK-Cu sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK-Cu is graded Cosmetic Clinical + Animal Studies, with 15 cited sources on its reference page and 122 indexed studies. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies.
Which is more accessible, GHK-Cu or AHK-Cu?
Neither GHK-Cu nor AHK-Cu is an FDA-approved drug. Catalog status: GHK-Cu, Cosmetic / Research; AHK-Cu, Cosmetic. GHK-Cu's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are GHK-Cu and AHK-Cu ever combined?
GHK-Cu and AHK-Cu appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…